**: The home of the instrument, unauthorized shall not be allowed**, and it can be done after 24 hours**.
A few days ago, Mindray's North American subsidiary announced that it has reached a new strategic agreement with AEGLE Medical Solutions (hereinafter referred to as "AEGLE"). Under the terms of the agreement, AEGLE will become the sole distributor of Mindray's Hepatus series of transient elastography diagnostic ultrasound systems.
Aegle is a long-time Ohio-based medical device distributor with over 25 years of experience in the medical industry. Committed to providing medical professionals with a consultative approach to help them evaluate and introduce new technologies into their clinical settings. The partnership with Mindray aims to provide a non-invasive solution to detect, diagnose and track patients' liver disease, helping to reduce the risk of pain and further complications that typically occur with other diagnostic methods such as liver biopsy.
Mindray entered the transient elastography market
In a press release, Wayne Quinn, President of Mindray North America, said, "As liver disease continues to spread, we recognize the importance of constantly finding new ways to provide better care to patients through innovative technologies and reliable quantitative tools. This allows their clinicians to get a clearer picture of their patients' liver health. ”
At present, it is believed that various types of chronic liver diseases, such as chronic viral hepatitis B and non-alcoholic fatty liver disease, can cause fibrotic changes in the liver, and then develop into cirrhosis, and even liver failure and hepatocellular carcinoma. The early stage of liver fibrosis is reversible, and if it can be identified early and intervened in time, it can better delay the progression of liver disease and improve the prognosis.
Transient elastography (TE), or liver elasticity testing, is recognized as a non-invasive quantitative detection of fibrosis. Being able to assess the degree of liver fibrosis by emitting sound waves and measuring the attenuation coefficient that they propagate through liver tissue can help doctors detect changes in stiffness of liver tissue early, providing an important tool for early diagnosis of fibrosis.
Mindray is the only company in the world that provides strain type elastography technology, shear wave elastography technology, and transient elastography technology with independent intellectual property rights. In 2020, Mindray entered the transient elastography market by launching the Milk Thistle Hepatus Non-invasive Quantitative Liver Ultrasound Instrument.
Hepatus 6 diagnostic ultrasound system.
Around June 2023, Mindray North America announced the launch of the Hepatus 6 diagnostic ultrasound system, which further opened up its position in the North American market while improving its product layout. This product combines transient elastography and diagnostic ultrasound in a single device, making it ideal for non-invasive detection, diagnosis and evaluation of liver disease.
"The king of domestic production going to sea", global layout
Mindray was originally founded in 1991 in a small office in Shekou Financial Building, Shenzhen. In the early days of its establishment, Mindray obtained two loans of 5.95 million yuan with the help of Shenzhen**, which became the first "east wind" that could gain a firm foothold in the early days of its business. In the second year, Mindray entered into independent R&D and independent production, cultivating its strength through differentiated play until it competed head-on with international giants.
It is reported that in the 30 years of development of Mindray Medical, which started from the monitor, it has taken a typical Chinese manufacturing enterprise to climb the road. After 30 years of development, it has become the leading medical device leader in China and the world, with self-research + mergers and acquisitions to lay out multiple product lines and enter overseas.
Today, Mindray has grown into China's largest and the world's leading medical device company. Its business segments cover life information and support, medical imaging, in vitro diagnostics and other fields, and its products cover 99% of the top tertiary hospitals and nearly 110,000 medical institutions in China, and are exported to more than 190 countries and regions, North America, Western Europe and other top hospitals in the world.
Headquartered in Shenzhen, China, it has 53 overseas subsidiaries in about 40 countries in North America, Europe, Asia, Africa, Latin America and other regions. It has 22 subsidiaries and more than 30 branches in China. It has established a R&D and innovation platform based on global resource allocation, with ten R&D centers distributed in Shenzhen, Wuhan, Nanjing, Beijing, Xi'an, Chengdu, Silicon Valley, New Jersey, Seattle and Europe, forming a huge global R&D, marketing and service network.
As China's "first brother in medical equipment", Mindray Medical is also the "king of domestic medical equipment". According to the export data of 2022, the export volume of medical devices in 2022 will burst out again, according to the data of the General Administration of Customs, the total export value of medical devices in China in January and November 2022 will reach 44417.9 billion yuan, and the annual export value is expected to be 478.5 billion yuan.
The king of the seas
Mindray, on the other hand, has the core pricing power in overseas markets and achieved revenue of 10 billion yuan, once again becoming the "king of domestic medical devices", and its overseas revenue mainly comes from monitoring, inspection, ultrasound products and overall solutions.
On August 30, 2023, Mindray Medical released its 2023 semi-annual report, with stable and bright performance as always, 184The revenue of 7.6 billion yuan increased by 20% year-on-year32%, net profit 644.2 billion yuan, a year-on-year increase of 2183%。The international market achieved an operating income of 66900 million yuan, a year-on-year increase of 101%, including an increase of 163%。
In the first half of 2023, Mindray Medical has broken through 168 new high-end customers, and more than 300 existing high-end customers have achieved horizontal breakthroughs in more products, while high-end customers in various production lines such as medical imaging and in vitro diagnostics are also accelerating.
Acquisition of Diasys
In addition, on July 31, Mindray also acquired a 75% stake in Diasys Diagnostic Systems ("Diasys"), a well-known German company, which has subsidiaries in North America, Europe, Latin America and Asia-Pacific, and production bases in Europe, Asia-Pacific and Latin America, with end customers in more than 140 countries around the world.
After the completion of the closing, Mindray will make full use of its past experience in cross-border M&A integration and management, gradually introduce and improve the first-chain platform of overseas IVD businesses such as chemiluminescence through Diasys, and strengthen the capacity building of overseas localized production, warehousing, logistics, and services, so as to lay a solid foundation for the comprehensive internationalization of IVD business.
Mindray Medical has also publicly stated that in the future, it will adhere to R&D investment, adhere to independent innovation, adhere to global layout, and continue to expand the breadth and depth of its business. It is hoped that it will be among the top 20 medical devices in the world in about five years, and that it will become one of the top 10 medical devices in the world through further efforts.
The cooperation with AEGLE is expected to further meet the needs of clinical refinement and personalized diagnosis and treatment decision-making, and is also another powerful tool for Mindray in the North American market. It is believed that its international status will be increasingly enhanced in the future, and the family of equipment will also pay close attention.